@article{JGO1534,
author = {Gayathri Nagaraj and Yousef Zarbalian and Karin Flora and Benjamin R. Tan Jr},
title = {Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6},
journal = {Journal of Gastrointestinal Oncology},
volume = {5},
number = {1},
year = {2013},
keywords = {},
abstract = {Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/1534}
}